Study Results Validate Use of Tumor Markers to Treat Metastatic Cancer
By LabMedica International staff writers Posted on 17 Jun 2019 |
A new study validated the use of tumor markers to select chemotherapy drugs for patients with metastatic pancreatic cancer (Photo courtesy of SPL).
Promising results obtained in a recently conducted pilot study demonstrated the feasibility of using molecular tumor markers as the basis for selecting the chemotherapeutic agents to use in patients with metastatic pancreatic cancer.
Investigators at Georgetown University (Washington, DC, USA) and collaborators at several other institutions carried out a study designed to assess the feasibility of following a treatment algorithm based on the expression of three published predictive markers of response to chemotherapy: ribonucleotide reductase catalytic subunit M1 (for gemcitabine); excision repair cross-complementation group 1 (for platinum agents); and thymidylate synthase (for 5-fluorouracil) in patients with untreated, metastatic pancreatic cancer.
Initially, 30 patients were enrolled in the study. However, 10 patients failed screening primarily due to inadequate tumor tissue availability. Of the remaining 20 patients, tumor biopsy analysis was used to assign them to one of seven doublet treatment regimens. Key secondary objectives included response rate (RR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Results revealed promising indications for progression-free survival and overall survival, with a partial response seen in 28% of patients and stable disease in 50% by completion of the study.
Based on the results from this pilot study, a larger phase II randomized trial of molecularly targeted therapy versus physicians' choice of standard of care has been initiated.
Results of the pilot study were discussed in the May 2, 2019, online edition of the Journal of Pancreatic Cancer.
Related Links:
Georgetown University
Investigators at Georgetown University (Washington, DC, USA) and collaborators at several other institutions carried out a study designed to assess the feasibility of following a treatment algorithm based on the expression of three published predictive markers of response to chemotherapy: ribonucleotide reductase catalytic subunit M1 (for gemcitabine); excision repair cross-complementation group 1 (for platinum agents); and thymidylate synthase (for 5-fluorouracil) in patients with untreated, metastatic pancreatic cancer.
Initially, 30 patients were enrolled in the study. However, 10 patients failed screening primarily due to inadequate tumor tissue availability. Of the remaining 20 patients, tumor biopsy analysis was used to assign them to one of seven doublet treatment regimens. Key secondary objectives included response rate (RR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Results revealed promising indications for progression-free survival and overall survival, with a partial response seen in 28% of patients and stable disease in 50% by completion of the study.
Based on the results from this pilot study, a larger phase II randomized trial of molecularly targeted therapy versus physicians' choice of standard of care has been initiated.
Results of the pilot study were discussed in the May 2, 2019, online edition of the Journal of Pancreatic Cancer.
Related Links:
Georgetown University
Latest Molecular Diagnostics News
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes
- Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury
- New Method for Lung Microbiomes Analysis Predicts Mortality in Children after Bone Marrow Transplant
- Novel Technique Detects Biomarkers for Kidney Diseases with Nephritic Syndrome
- Lipoprotein Blood Test Detects Hereditary Cardiovascular Risk
- Whole Genome Sequencing Detects Infection Transmission in NICU
- Novel Inexpensive, Shelf-Stable, Easy To Use Tests Bring Lab-Level Precision at POC
- World’s First One-Minute Hepatitis C Antibody Test Facilitates Quick Triage
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections